A Multicentre, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of Retigabine Immediate-release (IR) in Asian Adults With Partial Onset Seizures (Extension of Study RTG114855) [EXTENSION OF 700220875]
Phase of Trial: Phase III
Latest Information Update: 16 Oct 2017
At a glance
- Drugs Retigabine (Primary)
- Indications Partial epilepsies
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 11 Oct 2017 Status changed from active, no longer recruiting to completed.
- 12 Jan 2017 Planned End Date changed from 1 Dec 2017 to 1 Sep 2017.
- 19 Dec 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.